| Autor: |
Patel, Grisma, Edirisooriya, Monisha, Dey, Moloy, Parkar, Rosemeen |
| Zdroj: |
Current Problems in Cancer: Case Reports; 20220101, Issue: Preprints |
| Abstrakt: |
Central serous retinopathy (CSR) is a lesser-established ocular toxicity associated with BRAF/MEK inhibitors, a targeted treatment used in BRAF-mutated melanoma. This case study outlines a patient with metastatic cutaneous melanoma, who developed bilateral multifocal CSR secondary to dabrafenib and trametinib, two commonly used BRAF/MEK inhibitors. This report aims to improve the understanding of CSR as an adverse effect of BRAF/MEK inhibitors, including the potential for sight threatening ocular toxicity. It also aims to emphasise the importance of multi-specialty management to manage such toxicity while upholding delivery of cancer treatment in the best interests of the patient. In this case, the BRAF/MEK inhibitors were re-commenced at half dose and the CSR did not further progress, demonstrating an alternative option to halting treatment or switching to second-line therapy. Ultimately, a risk versus benefit approach is required, with decision making involving the multi-disciplinary team centred around an informed patient. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
